I will have more to say on SGLT2 synergy later today. Keep in mind that previous statin synergy was only on plaque reduction and that rosuvastatin could very well have still elicited better plaque reduction in BETonMACE. The Phase 2 ASSURE plaque reduction synergy was blaringly obvious, but this was a small trial and only 6 months in length and very different patient population.

There are MANY more beneficial pathways and mechanisms of action for apabetalone beyond plaque reduction that contribute to MACE risk reduction. The Phase 2 analysis of 5-point MACE didn't really show an obvious benefit of one statin over the other. And very few of those 5-point MACE that were analyzed were 3-point MACE. And very few were diabetics and probably none were recent ACS like in BETonMACE. Look at this post and the linked patent in that post for more details.

BDAZ